Thorsten BRAUN
Welcome,         Profile    Billing    Logout  
 15 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Braun, Thorsten
EPO-PRETAR, NCT03223961: A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Recruiting
3
124
Europe
EPREX, Epoetin alfa
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
05/22
05/24
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
IFM 2021-01, NCT05572229: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Recruiting
2
74
Europe
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide
University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
05/25
09/30
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia

Recruiting
2
44
Europe
Venetoclax, ABT-199
Groupe Francophone des Myelodysplasies, AbbVie
Chronic Myeloid Leukemia
02/26
10/28
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR

Recruiting
1/2
100
Europe
Pioglitazone, Avelumab
Versailles Hospital
Leukemia, Myeloid, Chronic-Phase
11/22
06/23
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Recruiting
1/2
64
Europe
Sulfasalazine
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
11/25
12/26
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Recruiting
1/2
36
Europe
Onureg + Venetoclax, CC-486 + ABT-199
Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie
Untreated Myelodysplastic Syndrome
11/25
11/28
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting
1/2
150
Europe
Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa
Groupe Francophone des Myelodysplasies, Celgene
MDS, Myelodysplastic Syndromes
05/27
11/27
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
eTHEMA, NCT05326919: The Patient Cohort of the National Center for Precision Medicine in Leukemia

Recruiting
N/A
3000
Europe
Biobanking
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable
03/42
03/42
DYNHAEMICS, NCT05304156: Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"

Recruiting
N/A
200
Europe
Biobanking blood and bone marrow specimens
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
04/26
05/26

Download Options